UFP Technologies Q3 sales beat estimates helped by MedTech growth

UFP Technologies

03/11/2025 21:17

Overview

UFP Technologies Q3 sales rise 6.5% yr/yr, beating analyst expectations

Net income for Q3 remains flat at $16.4 mln, impacted by increased labor costs

Company expands operations in Dominican Republic, launches new robotic surgery programs

Outlook

Company expects significant revenue from new robotic surgery programs in 2026 and beyond

UFP Technologies in talks to extend and expand contract with largest customer

Company plans continued expansion in Dominican Republic

Result Drivers

MEDTECH SALES - MedTech sales increased 7.3%, offsetting a decline in non-medical sales

LABOR COSTS - Incremental $3 mln labor costs at Illinois AJR facility impacted net income

DOMINICAN REPUBLIC EXPANSION - Progress in ramp-up and qualification of programs in new Santiago facility

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$154.55 mln
$149.60 mln (4 Analysts)
Q3 EPS
$2.12
Q3 Net Income
$16.38 mln
Q3 Gross Profit
$42.74 mln
Q3 Operating Income
$23.37 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for UFP Technologies Inc is $329.50, about 41.5% above its October 31 closing price of $192.64

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nGNX6TbGnz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)